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ABSTRACT
The overall survival rate for patients diagnosed with lung cancer is still extremely
low and many affected patients are not eligible for first-line treatments such as
surgery, chemotherapy, and radiation for the treatment due to the severe side effects
associated with these therapies. Paclitaxel (PTX) along with imatinib mesylate are
currently first-line therapies for many types of cancer (Kelly 2001, Schiller 2002).
However, the successful delivery of paclitaxel faces many challenges due to its
lipophilic nature and high protein affinity, which often results in low bioavailability.
Solubilization of drugs such as PTX, enhanced tumor accumulation, and toxicity
attenuation of such therapeutics can be enhanced via targeted delivery to tumors using
nanoparticles (NPs). For example, chemotherapeutic drugs such as PTX and
doxorubicin have been encapsulated singularly in micelles (Jinhyang 2012) and
nanoliposomes (Zhang 2011), thereby increasing the efficacy of radiation therapy
against in vitro lung cancer cells and in animals, demonstrating the success of
nanoparticle-mediated treatment of cancer. Current cancer treatment, however,
revolves around the tandem delivery of PTX and therapeutics such as imatinib,
doxorubicin, and carboplatin. Unfortunately, multi-drug delivery is not easily achieved
with single-agent delivery systems demonstrating the need for a nanoparticle system
capable of delivering multiple drugs in tandem directly to the tumor site(s).
While the enhanced permeability and retention (EPR) effect has served as a key
rationale for using nanoparticles to treat solid tumors, as it allows for increased uptake
of NPs at the tumor site, it often does not enable uniform delivery of these particles to
all regions of tumors. Tumor-penetrating peptides show great promise in overcoming

the relevant physiological barriers preventing accumulation and penetrating into the
avascular region of tumors. iRGD (internalizing RGD, CRGDKDPDC), has been
shown to effectively target and penetrate both in vitro multicellular spheroids (MCS)
and in vivo animal model tumors when conjugated to drugs or nanoparticles (Sugahara
2010). For the described research, I hypothesize that iRGD-conjugated nanoparticles
containing PTX and imatinib will more effectively home to and penetrate lung cancer
tumor spheroids for more effective treatment of this dismal disease.
In particular, acetalated dextran (Ac-Dex) nanoparticles were synthesized to
contain PTX and/or imatinib. These particles were shown to have sizes appropriate for
systemic delivery (approximately 250 nm) and exhibited smooth, round morphology.
All particle systems exhibited favorable homogeneity as evidenced by low
polydispersity index values (less than 0.20) and were nearly neutral in charge with
zeta potentials near zero. Both PTX and imatinib were successfully loaded into the
nanoparticles with 50 and 14 weight % loading, respectively. 80% of iRGD was
conjugated to the nanoparticles and the peptide showed affinity for A549 lung
adenocarcinoma cells in vitro. A549 multicellular spheroids were generated to allow
for evaluation of the newly developed therapeutics. Finally, in vitro analysis using
A549 cells showed that the drug-loaded nanoparticles were more effective at killing
cells than pure drugs. Overall, this work shows the promise of Ac-Dex drug-loaded
nanoparticles conjugated with iRGD to enhance the treatment of lung cancer.
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CHAPTER 1

INTRODUCTION

1.1 Background and Treatment of Lung Cancer
The optimization and improvement of cancer therapeutics is currently an
important objective of pharmaceutical research since there are still many problems
faced in the treatment of many types of cancer including lung, glioblastoma, and
pancreatic cancers, which have extremely poor treatment success rates (Sneed 1998).
Therefore, the improvement of cancer treatment options through methods such as
targeting and controlled release of therapeutic agents is in great need.
Lung cancer is the second most commonly diagnosed cancer and the most fatal of
all types of cancers, accounting for about one out of five malignancies in men and one
out of nine malignancies in women (NCI 2014). There are two major types of lung
cancer: small cell lung cancer (SCLC), which is also called oat cell cancer because the
cells resemble oat grains, and non-small cell lung cancer (NSCLC). The
aggressiveness of this disease and treatment options depend on the type and stage of
cancer diagnosed. Available treatment options might include surgical resection,
chemotherapy, and/or radiation. Since many types of lung cancer grow quickly and
spread rapidly, and because the lungs are vital organs, early detection and prompt
treatment (usually involving an initial surgery to remove the tumor) is critical to
ensure increased patient survivability.
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The majority of lung cancers are classified as non-small cell lung cancer, where
about half of these are squamous cell carcinomas (SCC). SCC, sometimes called
epidermoid carcinoma, is more prevalent in men and arises in the lining of the large
air passageways or bronchi. Another common type of NSCLC is adenocarcinoma,
which occurs at the outer edges of the lung. A small percentage of NSCLC are
large-cell carcinomas, which usually develop in the smaller bronchi. Non-small cell
lung cancer that begins at the top of the lung sometimes spreads to the nerves and
blood vessels leading to the arm. All three subtypes of NSCLC develop differently and
treatment options are often based on the location of the particular cancer and its rate of
spread (NCI 2014).
Early diagnosis and intervention can improve the survivability of patients
diagnosed with lung cancer. Minimally invasive treatments such as video-assisted
thoracoscopy and thoracotomy surgery (VATS) and radiofrequency ablation (RFA)
can be used for the detection of lung cancer in its early stages. Comprehensive
multi-modality treatment with a combination of local and systemic therapy can
maximize the treatment outcome for more advanced-stage lung cancers. These
therapies can include chemotherapy, targeted therapy, and rehabilitation.
The five-year survival rates for patients diagnosed with non-small cell lung cancer
who are eligible to undergo treatment can be found in Table 1. As seen in this figure,
even patients who are diagnosed with Stage 1 NSCLC have only a 54% rate of
survival after five years. This is often because even though patients diagnosed with
Stage 1 cancer tolerate and survive their first round of treatment well, recurrences of
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Table 1: Five-year survival rates of patients diagnosed with non-small cell
lung cancer (NSCLC) (NCI 2014).

Stage

5 Year Survival Rate

0

Too few cases to evaluate

I

54%

II

35%

IIIA

10 - 15%

IIIB

< 5%

IV

< 2%

3

the disease are common and more aggressive. Unfortunately, very few patients with
Stages IIIB or V NCSLS will be alive five years after their initial diagnosis. These
dismal statistics show the importance in improved treatment options for patients
diagnosed with NSCLC throughout the course of their disease.
Surgical resection is the standard of care for early stage lung cancer, however,
only 25% of patients have resectable disease at the time of diagnosis (Wisnivesky
2005). This can be attributed to the poor health of patients diagnosed with NSCLC as
many of these patients are former smokers with other severe health issues such as
chronic obstructive pulmonary disease (COPD) and heart disease. In addition, these
patients are often of an advanced age, indicating that they are often not healthy enough
to undergo aggressive cancer treatments.
In regards to chemotherapeutics, there are several drug classes used in
combination with one another as the first-line therapies for many types of NSCLC
(Kelly 2001, Schiller 2002). Of these drugs, there are many FDA-approved
compounds currently used clinically for the treatment of NSCLC including paclitaxel
(Jinhyang 2012) and cisplatin (Zhang 2011). In addition, there are many drugs under
investigation for the treatment of NSCLC such as imatinib (Zhang 2003), everolimus
(Kochanski 2012), and artesunate (Zhao 2011). While these particular drugs are not
yet widely used in the treatment of NSCLC, they are currently approved for the
treatment of other types of cancer.
The ability of chemotherapeutics to kill cancer cells depends on their ability to
halt cell division. Usually, these types of drugs work by damaging the RNA or DNA
that tells the cell how to copy itself in division (Vermeulen 2003). If the cells are
4

unable to divide, they subsequently die. The faster the cells are able to divide, the
more likely it is that chemotherapy will kill these cells, causing the tumor to shrink.
This is the main tenant behind how chemotherapeutics work in that they attack rapidly
growing cancer cells while sparing the majority of the body’s healthy tissues.
However, this means that these therapeutics will also attack rapidly growing cells in
other parts of the body including hair follicles and gastrointestinal tract.
Chemotherapeutics ultimately induce apoptosis (self-death or cell suicide). Drugs
that disrupt mitotic progression, which are commonly referred to as antimitotics, are
used extensively for the treatment of cancer. Paclitaxel (Taxol®, Bristol-Myers
Squibb Co., Princeton, New Jersey), which belongs to this class of chemotherapy
drugs (Marupudi 2007), was originally derived from the bark of Taxus brevifolia
(pacific yew tree). The structure of PTX can be seen in Figure 1. PTX binds to
polymerized tubulin in cells, thereby preventing microtubule formation and promoting
microtubule stabilization against disassembly. This in turn inhibits mitosis, and
therefore prevents cancer growth.
Imatinib mesylate (also known as simply imatinib, STI571, or Gleevec from
Novartis Pharmaceutical Inc.), is a recently FDA-approved drug used for the treatment
of chronic myelogenous leukemia and gastrointestinal stromal tumors. The structure of
imatinib can be seen in Figure 2. Imatinib is an adenosine triphosphate (ATP)
analogue, and it competitively binds to and inhibits the oncogene BCR-ABL tyrosine
kinase, which results from the chromosomal translocation (Zhang 2003). While
traditional cytotoxic cancer treatments such as chemotherapy or radiation therapy kill
all dividing cells, imatinib acts on a molecular target by a mechanism that is more
5

Figure 1: Schematic of the chemical structure of paclitaxel (PTX).

6

Figure 2: Schematic of the chemical structure of imatinib mesylate (IM).

7

specific to cancer cells (Timeus 2012). Therefore, it is advantageous to use imatinib
for the treatment of cancer because it is more specific to damaging cancer cells,
thereby sparing healthy tissue. In particular, imatinib mesylate (IM) has been
demonstrated to inhibit the growth and proliferation of gastrointestinal stromal tumors
(GIST), and to induce the complete or partial clinical remission in GIST patients. In
addition, IM was showed to inhibit the growth of dermatofibrosarcoma protuberans
(DFSP) through inhibiting the platelet-derived growth factor (PDGF) receptor (Zhang
2003). Despite encouraging pre-clinical data, IM has had limited clinical efficacy
against neuroblastoma tumors when used as a single agent. In regards to lung cancer,
it has been demonstrated that A549 cells overexpress PDGF receptor alpha (PDGFR
α), one of the known potential targets for imatinib. The inhibitory effect of imatinib on
A549 cells is likely mediated through inhibition of this receptor via phosphorylation
(Zhang 2003). Overall, these results show the promise that IM has to selectively target
and treat a wide variety of tumors.
Despite the widespread use of the aforementioned therapeutics for the treatment
of cancer, as with other types of chemotherapeutics, they often face challenges in
therapeutic efficacy due to limitations in systemic delivery. In particular, the delivery
of paclitaxel faces many challenges due to its lipophilic nature and high protein
affinity, which ultimately results in low bioavailability due to its very minimal
solubility in water. Also, while the addition of Cremophor EL (a type of
polyethoxylated castor oil) and ethanol in the intravenous Taxol® formulation is used
to increase the solubility of PTX, these additives often cause severe side effects in
many patients (Carvalho 2011).
8

It has been shown that drug solubilization, an increase in tumor accumulation, and
toxicity attenuation of drugs can be enhanced via the use of nanoparticles for the
delivery of anti-cancer agents. For example, single-agent paclitaxel plays a central role
in the treatment of advanced NSCLC. As mentioned previously, the use of this drug is
limited, however, by its poor solubility and by the toxicities associated with additives
in the formulation Taxol®. Abraxane is an FDA-approved therapeutic that is
comprised of a paclitaxel protein (albumin)-bound nanoparticle system delivered to
patients via an injectable suspension. These nanoparticles were developed by
American BioScience, Inc. (Santa Monica, California) and are Cremophor EL- and
ethanol-free. That nanoparticles are approximately 130 nm size and have been
designed to address the solubility limitations of traditional paclitaxel (Green 2006).
In addition, paclitaxel-loaded poly(ethylene glycol) and poly(lactic-co-glycolic
acid) (PLGA)-based nanoparticles have been developed where this new system is
more cytotoxic on Hela cells than Taxol® (Goodman 2008). In contrast to Cremophor
EL, no cytotoxicity of the polymers that make up these nanoparticles was observed
(Danhier 2009). In regards to IM, imatinib mesylate has also been successfully loaded
into PEG-PLGA nanoparticles as an model system for successful intracellular delivery
of molecular targeting drugs in excised veins (Kimura 2008). Similarly, imatinib
mesylate-chitosan poly(ε-caprolactone) (PCL) nanoparticles have been investigated
for their potential in enhancing controlled release and improving chemotherapeutic
efficiency of IM (Cortese 2014). In regards to tandem delivery vehicles, dual-drug
loaded nanoparticles containing PTX and gemcitabine have been used against human
pancreatic cancer cells and their cytotoxicity was significantly improved compared to
9

the free drugs (Aryal 2010). A study from the Acharya lab demonstrated that
dual-drug loaded nanoparticles work in a synergistic manner lowering the dose of
administration and time of action of the drugs, ensuring that both drugs reach the
targeted cells specifically and maximize cytotoxicity while minimizing the chances of
cell resistance to any one drug (Acharya 2011). Current treatment, however, revolves
around the combined delivery of multiple therapeutics, and this is not easily achieved
with single-agent nanoparticle systems demonstrating the need for a therapeutic
capable of tandem delivery of chemotherapeutics. Overall, these studies show the
feasibility in using drug-loaded nanoparticles to enhance the treatment potential of
currently available anticancer therapeutics.

1.2 Nanoparticle-Based

Drug

Delivery

Platforms

and

the

Use

of

Tumor-Penetrating Peptides
There are currently many drug delivery systems in development for the treatment
of lung cancer and some of them have achieved moderate progress and have brought
about the considerable development in this area of research. In fact, several targeted
drug and gene delivery systems have been developed to treat NSCLC more effectively.
For example, Sundaram et al. developed a conjugate drug system containing deslorelin
(an anti-angiogenic compound) and docetaxel (a traditional chemotherapeutic
compound) where the drugs were conjugated with the peptide RGD and delivered in
vivo (Sundaram 2009). The in vitro and in vivo efficacy of these peptide-conjugated
drugs were evaluated in H1299 (NSCLC) cells and xenografts in athymic nude mice
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and the results showed that the conjugated peptide enhanced both the in vitro and in
vivo efficacies significantly.
Nowadays, much attention is being focused on nanotechnology, where this refers
to the interactions of molecular components and engineered materials at the nanoscale.
Nanomaterials are typically clusters of atoms, molecules, and molecular fragments
formed into incredibly small particulates. Nanometer-sized particles have novel
optical, electronic, and structural properties that are not always present in individual
molecules or bulk solids (Sajja 2009). The concept of nanoscale devices has led to the
development of biodegradable self-assembled nanoparticles, which have been
engineered for the targeted delivery of anticancer drugs and imaging contrast agents.
Nanoconstructs such as these can serve as customizable, targeted drug delivery
vehicles capable of ferrying large doses of chemotherapeutic agents or therapeutic
genes into malignant cells while sparing healthy cells. Such ‘‘smart’’ multifunctional
nanodevices hold out the possibility of radically changing the practice of oncology,
allowing easy detection and then followed by effective targeted therapeutics at the
earliest stages of the disease (Sinha 2006). In particular, polymeric nanoparticles
(PNPs) are defined as particulate dispersions or solid particles with size in the range of
10 - 1000 nm. There has been considerable research interest in the area of drug
delivery using particulate delivery systems as carriers for small and large molecules.
The techniques for the preparation of nanoparticles depend on the particular
application and or drug to be loaded into the nanoparticle system. A mini-review of
several common methods for the preparation of nanoparticles from dispersions of

11

preformed polymer can be seen in Table 2 and methods for preparation of
nanoparticles from polymerization of monomers in Table 3.
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Table 2: Review of the common methods used for the preparation of
nanoparticles.

Preparation Method
Solvent evaporation

Preparation Details
Solvent

evaporation

was

the

first

method

developed to prepare PNPs. In this method, polymer
solutions are prepared in volatile organic solvents and
vigorously mixed with aqueous solutions so that
emulsions are formulated. This emulsion is converted
into a nanoparticle suspension upon evaporation of the
solvent from the polymer, which is allowed to diffuse
through the continuous phase of the emulsion.
Nanoprecipitation

Nanoprecipitation is also called the solvent
displacement method. It involves the precipitation of a
preformed polymer from an organic solution and the
diffusion of this organic solvent into the aqueous
medium in the presence or absence of a surfactant
(Fessi 1989, Barichello 1999, Galindo-Rodriguez 2004,
Ganachaud 2005) .

Emulsification/solvent
diffusion

This method is a modified version of solvent
evaporation method. The encapsulating polymer is
dissolved into a partially water soluble solvent such as
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propylene carbonate and saturated with water to ensure
the initial thermodynamic equilibrium of both liquids.
To produce the precipitation of the polymer and the
consequent formation of nanoparticles, it is necessary
to promote the diffusion of the solvent of the dispersed
phase by dilution with an excess of water when the
organic solvent is partly miscible with water or with
another

organic

solvent

in

the

opposite

case.

Subsequently, the polymer-water saturated solvent
phase is emulsified in an aqueous solution containing a
stabilizer, leading to solvent diffusion to the external
phase and the formation of nanoparticles, according to
the oil-to-polymer ratio. Finally, the solvent is
eliminated by evaporation or filtration, according to its
boiling point (Niwa 1993).
Salting out

The salting out method is based on the separation
of a water miscible solvent from aqueous solution via a
salting out effect. The salting out procedure can be
considered

as

a

modification

of

the

emulsification/solvent diffusion (Fessi 1989, Jeon 2000,
Jeong 2001, Kostag 2010, Rao 2011) .
Dialysis

Dialysis offers a simple and effective method for

14

the preparation of small, narrow-distributed PNP. A
polymer is dissolved in an organic solvent and placed
inside a dialysis tube with proper molecular weight cut
off. Dialysis is performed against a non-solvent
miscible with the former miscible. The displacement of
the solvent inside the membrane is followed by the
progressive aggregation of polymer due to a loss of
solubility

and

the

formation

of

homogeneous

suspensions of nanoparticles (York 1999, Kawashima
2001, Rao 2011).
Supercritical fluid

The need to develop environmentally safer

technology (SCF)

methods for the production of PNP has motivated
research on the utility of supercritical fluids as more
environmental friendly solvents, with the potential to
produce PNPs with high purity and without any trace of
organic solvent. Supercritical fluid and dense gas
technology are expected to offer an interesting and
effective technique of particle production, avoiding
most of the drawbacks of the traditional methods. Two
principles have been developed for the production of
nanoparticles using supercritical fluids: 1) Rapid
expansion of supercritical solution (RESS) and 2)

15

Rapid expansion of supercritical solution into liquid
solvent (RESOLV) (York 1999, Kawashima 2001, Rao
2011).
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Table 3: Overview of the methods used for the preparation of nanoparticles
from the direct polymerization of monomers.

Preparation Method
Emulsion

Preparation Details
Emulsion polymerization is one of the fastest
methods for nanoparticle preparation and is readily
scalable. The method is classified into two categories,
based on the use of an organic or aqueous continuous
phase. The continuous organic phase methodology
involves the dispersion of monomer into an emulsion or
inverse microemulsion, or into a material in which the
monomer is not soluble (non-solvent). Polyacrylamide
nanospheres were produced by this method. As one of
the first methods for production of nanoparticles,
surfactants or protective soluble polymers have been
used to prevent aggregation in the early stages of
polymerization (Pinto Reis 2006).

Interfacial
polymerization

This method involves step polymerization of two
reactive monomers or agents, which are dissolved
respectively in two phases (i.e., continuous- and
dispersed-phases). A reaction takes place at the
interface of the two liquids to form nanoparticles in
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suspension. (Lambert 2000, Charcosset 2006, Gaudin
2008, Wu 2009, Landfester 2010)
Controlled/Living

Weak intramolecular interactions among polymer

radical polymerization chains
(C/LRP)

can

be

exploited

to

form

organized

nanostructured materials, provided the polymers have
uniform dimensions, topologies, compositions and
functionalities. Particular emphasis is placed on
structure–reactivity correlations and ‘‘rules’’ for catalyst
selection in atom transfer radical polymerization
(ATRP), for chain transfer agent selection in reversible
addition-fragmentation

chain

transfer

(RAFT)

polymerization, and for the selection of an appropriate
mediating agent in stable free radical polymerization
(SFRP), including organic and transition
persistent radicals (Braunecker 2007).
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metal

With the increased use of nanoparticles for drug delivery applications, it has been
noted that there are many advantages in using these systems over traditional
systemically delivered pure drug systems (Kayser 2005, Abhilash 2010). Such
advantages in the use of polymeric nanoparticle systems include, but are not limited to
the following:



The increased stability of any volatile pharmaceutical agents present.



The fabrication of large quantities of particles is easy and cheaply done using a
multitude of methods.



A significant improvement over traditional oral and intravenous methods of
administration in terms of efficiency and efficacy is often seen.



There is delivery of a higher concentration of a pharmaceutical agent to a
desired location.



Modified drug release allows for tailoring of drug delivery.



They can be applied to a wide variety of drug delivery fields including cancer
therapy, delivery of vaccines, contraceptives, and targeted antibiotics.



The can be easily incorporated into other activities related to drug delivery,
including tissue engineering.

The enhanced permeability and retention (EPR) effect involves the extravasation
of nanoparticles from “leaky” tumor vasculature into tumor tissue. While the EPR
effect has served as the key rationale for using nanoparticles to treat solid tumors, it
often does not enable uniform delivery of these particles to all regions of tumor.
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Furthermore, while ligands that target cancer cells can often increase the intracellular
concentration and cytotoxicity of targeted nanoparticles, the intratumoral penetration
is not improved significantly compared with non-targeted nanoparticles (Jain 2010).
This is due to multiple factors including ineffective targeting ligands, the tumor-blood
vessel wall barrier, slow diffusion into the interstitium of tumors, and physiological
barriers of the tumor. These barriers include the lack of functional lymphatic vessels,
elevated interstitial fluid pressure, and dense extracellular matrix (Jain 1990).
Tumor-penetrating peptides show great promise in overcoming many barriers that
prevent the accumulation and penetration of nanoparticles into the avascular region of
tumors. iRGD (internalizing RGD, CRGDKDPDC), a cyclic peptide, has been shown
to effectively target and penetrate both in vitro three-dimensional multicellular
spheroids and in vivo animal model tumors when conjugated to drugs or nanoparticles
(Sugahara 2010). The peptide iRGD initially accumulates at the surface of αν
integrin-expressing cells and tissue in tumors. This is advantageous in that integrins
are overexpressed in many types of tumors and tumor-associated vasculature and
tissue while being minimally expressed in healthy tissue (Waite 2009, Desgrosellier
2010). Once iRGD reaches the integrin target, it is cleaved by cell surface-associated
proteases to expose the C terminus and CandR element which then mediates binding
to neuropilin-1, resulting in penetration of the cancerous cells and tissues as seen in
Figure 3. iRGD has been used effectively with many new and already FDA-approved
nanoparticle systems and drugs such as doxorubicin, Abraxane®, Doxil® and
trastuzumab to enhance tumor penetration and treatment efficacy in in vivo models
(Sugahara 2009). In addition, it enhances tumor penetration when co-administered
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Figure 3: Illustration of iRGD-conjugated acetalated dextran (Ac-Dex)
nanoparticles developed in this research where A) depicts the peptide cleavage
and penetration mechanism of the iRGD peptide and B) depicts tumor tissue
penetration by the nanoparticles due to the presence of iRGD.
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with drugs and particles.
The contribution of the therapeutic nanoparticle systems developed in this current
research lies in the production of a system that will be easier to deliver to patients by
combining multiple agents into one platform. Furthermore, it will allow not only for
the direct targeting of anticancer agents to lung tumors but will induce penetration of
the nanoparticle into tumor tissue, which can potentially allow for a lower dose of the
drugs to be used due to increased specificity (Simberg 2007, Karmali 2009, Ruoslahti
2010). The potential to lower the dosage of chemotherapeutic drugs using a
nanoparticle drug delivery system could result in a treatment that is both safer for
patients and easier to tolerate, especially for those that are not ideal candidates for
aggressive treatment.
Both the elderly and patients with morbidities such as chronic obstructive
pulmonary disease (COPD) could benefit greatly from this type of treatment since
they are usually neither eligible for surgery nor healthy enough for chemotherapy
(Schroedl 2012). Since 50 - 80% of lung cancer patients have COPD (Young 2009),
there is a significant portion of the population that could benefit from a more targeted,
safer treatment option.

1.3 Multicellular Spheroids (MCS) in Cancer Treatment Evaluation
Determining

whether

or

not

nanoparticles

will

penetrate

the

tumor

microenvironment is often difficult and while cell uptake studies are most commonly
used to show this potential, they bear minimal physiological resemblance to tumors.
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Conventional two-dimensional (2D) cell culture techniques have been utilized for
decades to test the efficacy of anti-cancer therapeutics despite limited translation of
the given results into in vivo models. The use of three-dimensional (3D) muticellular
tumor spheroids (MCS) have been used to overcome these limitations. 3D MCS are
clusters of cells that compact to form tight spheroids in vitro when cell-to-cell
interactions dominate over cell-to-substrate interactions, as seen in Figure 4. These
systems are advantageous in vitro models as they are vastly different from monolayer
cultures with respect to gene activation, antigen expression, and growth (Ingram
2010).
MCS can mimic avascular in vivo tumors in that they have diffusion limitations
for many molecules, including oxygen, and this inefficient mass transport leads to
metabolic waste accumulation inside the MCS so that they display a layer-like
structure comprised of a necrotic core surrounded by a viable rim of cells (Lin 2008).
It is usually the center of tumors that exhibit a hostile microenvironmrnt, as these
regions harbor the most aggressive tumor cells, which will regenerate if they are not
eliminated. MCS have been effectively used to study many types of therapeutics
including nanoparticles, chemotherapeutics, and radiation where the MCS show
significant differences in reponse in comparison to 2D cell monolayers (Goodman
2007, Goodman 2008). This illustrates imparts the importance of these systems in
optimizing drug and nanoparticle systems for systemic delivery to tumors.
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Figure 4: Schematic depicting the formation of spheroids for loose cell aggregates
into a compact spheroid following a brief delay period in formation.
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1.4 Acetalated Dextran (Ac-Dex) as a Novel Drug Delivery Platform
Acetalated dextran (Ac-Dex) is a newly developed polymer in which pendant
acetal groups are reacted onto hydroxyl groups present on the backbone of dextran to
give this polymeric compound unique characteristics. The reaction of dextran with
2-methoxypropene leads to the formation of both cyclic and acyclic acetals, causing a
switch in solubility and providing a trigger for acid-mediated degradation (Broaders
2009). Cyclic and acyclic acetals have completely different rates of hydrolysis (Fife
1965) and the amount of each present can be tailored by the extent of reaction
allowing for the modulation of degradation rates from hour to weeks (Meenach 2012).
In addition to allowing for tunable degradation, Ac-Dex has solubility properties
opposite of those of parent dextran, namely that it is soluble in organic solvents and
insoluble in water allowing for the processing of Ac-Dex into nanoparticles via
standard emulsion techniques (Bachelder 2008). Furthermore, Ac-Dex has pH neutral
degradation by-products (parent dextran and small amount of acetone and methanol)
and is acid sensitive. At low pH Ac-Dex degradation occurs more quickly whereas at
higher pH, the polymer degrades more slowly. In vitro assays have indicated that
Ac-Dex and its degradation by-products are as safe as the FDA-approved polymer
poly(lactic-co-glycolic acid) (PLGA) (Bachelder 2008), which is commonly used in
polymeric nanoparticle formulations. The use of Ac-Dex for the tandem delivery of
agents significantly advances the development of a targeted biodegradable nanocarrier
in that the carrier can be made to degrade fully within a day or up to a week without
harmful polymer accumulation or degradation by-products. Thus far, Ac-Dex has been
used in particle formulations for applications in immunology/vaccines (Broaders 2009,
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Kauffman 2011), tumor targeting (Beaudette 2009), improved storage of therapeutics
(Kanthamneni 2012), and pulmonary therapeutics (Meenach 2012).

1.5 Research Aims and Objectives
The overall aim of this project was to develop and optimize acetalated
dextran-based

peptide-conjugated polymer nanoparticles,

which can deliver

anti-cancer agents in tandem to allow for enhanced targeting and treatment of
non-small cell lung cancer. The specific research for this project include:


To synthesize acetalated dextran-based iRGD-conjugated nanoparticles loaded
with paclitaxel and/or imatinib mesylate.



To

evaluate

and

optimize

the

physicochemical

properties

the

peptide-conjugated Ac-Dex nanoparticles.


To assess the efficiency of the proposed nanoparticle system in the treatment
of non-small cell lung cancer using in vitro methods.
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CHAPTER 2

MATERIALS AND METHODS

2.1 Materials
Phosphate buffered saline (PBS), resazurin (sodium salt, pure, high purity
biological stain), glycine, Dulbecco’s Modified Eagle Medium (DMEM), and
Fungizone® were obtained from Fisher Scientific (Kansas City, MO, USA). Paclitaxel
was obtained from LC Labs (Woburn, MA, USA; 99.5% purity). Tween 20,
Kolliphore EL (previously known as Cremophor EL), dextran (average molecular
weight 9,000 - 11,000), dimethyl sulfoxide (DMSO, ≥ 99.9%), poly(vinyl-alcohol)
(PVA, MW 13,000 - 23,000), pyridinium p-toluenesulfonate (PPTS, 98%), fluorescein
isothiocyanate (FITC, HPLC grade, ≥ 90%), 2-methoxypropene, deuterium oxide
(D2O), deuterium chloride solution (DCl), dichloromethane (DCM, ≥ 98%),
triethylamine (TEA), methanol (HPLC grade, ≥ 99.9%), acetone (HPLC grade, ≥
99.9%), acetonitrile (HPLC grade, ≥ 99.9%), and fetal bovine serum (FBS) were
obtained from Sigma-Aldrich (St. Louis, MO, USA). Imatinib mesylate (Imatinib or
IM) was purchased from Adipogen International, Inc. (San Diego, CA, USA).
Lysotracker red, calcein AM, ethidium homodimer-1 (EthD-1), sodium pyruvate, and
Pen-Strep were purchased from Life Technologies (Carlsbad, CA, USA). Collagen (rat
tail type Ι) was obtained from Discovery Labware, Inc. (Two Oak Park, Bedford, MA,
USA). Poly(2-hydroxyethyl methacrylate) (pHEMA) was obtained from Polysciences,
Inc.

(Warrington,

PA,

USA).

Vectashield
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hardset

mounting

media

with

4',6-diamidino-2-phenylindole (DAPI) was obtained from Vector Labs, Inc.
(Burlingame, CA, USA). All materials were stored in the conditions recommended by
the manufacturer and were used as received.

2.2 Synthesis and Characterization of Acetalated Dextran (Ac-Dex)
Ac-Dex was synthesized by the reaction of dextran with 2-methoxypropene as
seen in Figure 5. 1 g of lyophilized dextran (9,000 - 11,000 MW) was mixed well with
15.5 mg pyridinium p-toluenesulfonate in 10 mL of anhydrous DMSO to allow for
complete dissolution of the dry components. The reaction was initiated by adding 1
mL of 2-methyoxypropene, which added the acetal groups (both cyclic and acyclic) to
the parent dextran. The reaction proceeded for five minutes to produce fast degrading
Ac-Dex (Bachelder 2008, Broaders 2009). The reaction was then quenched with 1 mL
of triethylamine (TEA), followed by precipitation in basic water (pH 9.5), isolation via
filtration, and lyophilization. Basic water was made by mixing TEA in deionized water
for a final pH value of 9.5. This solution prevents the early degradation of
pH-sensitive Ac-Dex.
1

H-NMR analysis was performed to provide information on the relative cyclic to

acyclic ratio of acetal groups of the newly synthesized Ac-Dex polymer. 10 mg of
Ac-Dex was suspended in an NMR tube with 700 μL of D2O (deuterium oxide) and 30
μL of DCl (deuterium chloride), where the DCl was used to facilitate fast degradation
of the Ac-Dex in the solution. During the degradation of Ac-Dex, hydrolysis of one
cyclic acetal produces one acetone molecule whereas hydrolysis of one acyclic acetal
28

Figure 5: Schematic showing the reaction for the synthesis of acetalated dextran
(Ac-Dex). Dextran was reacted with 2-methoxypropene and a catalyst in DMSO
to form acyclic and cyclic acetalated dextran.
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produces one acetone and one methanol molecule. Therefore, from the relative ratio of
the peaks from acetone, methanol, and the cyclic to acyclic ratio of acetal substitution
and degrees of hydroxyl substitution per 100 glucose could be determined using
1

H-NMR (Broaders 2009). The cyclic to acyclic acetal ratio will be further referred to

as the CAC.

2.3 Synthesis, Optimization, and Characterization of Drug-Loaded Ac-Dex
Nanoparticles
Single emulsion (water/organic or W/O) nanoparticle synthesis techniques using
ultrasonic probe sonication were used to form particles loaded with paclitaxel (PTX)
and imatinib mesylate (IM). The initial theoretical encapsulation efficiency for the
nanoparticles was 0.1 weight % and 10 weight % for PTX- and IM-loaded
nanoparticles, respectively. For PTX-loaded nanoparticles, 0.5 mg of PTX was
dissolved into 1 mL of DMSO, which resulted in a concentration of 0.5 mg/mL. For
Imatinib-loaded nanoparticles, 50 mg of PTX was dissolved into 1 mL of DMSO,
which resulted in a concentration of 50 mg/mL.50 mg of Ac-Dex was then transferred
to a 20 mL scintillation vial followed by 900 μL of dichloromethane and 100 μL of the
drug/DMSO solution (0.5 mg/ml PTX in DMSO or 50 mg/mL Imatinib in DMSO),
resulting in the final organic (O) solution. Then, 2 mL of 3 % w/v poly (vinyl alcohol)
(PVA) in phosphate buffered saline (PBS), the aqueous phase (W), was added as to
the organic solution and the vial was transferred to an ice bucket. The O and W
solutions were sonicated for 30 seconds (QSonica Q500, 0.5 inch flat tip, amplitude of
50 %, 1 second on/off pulse) and then the resulting emulsion was poured into a stirring
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solution 40 mL of 0.3 % w/v PVA in PBS and stirred for four hours. After particle
hardening and solvent evaporation, the solution containing the nanoparticles was
centrifuged at 10,000 rpm (13,571 rcf) for 10 minutes.
After centrifugation, the supernatant solution was decanted and 1 mL of basic
water (pH 9.5) was added to each tube. The resulting particle pellets were then
resuspended in the basic water using a pipette and water bath sonication, as needed.
The remainder of the tubes with the resuspended nanoparticles was filled with basic
water and this centrifugation and washing step was repeated until the particles had
been washed three times. After the final decantation, the particles were suspended in 1
mL of basic water, and this solution was then transferred to a 5 mL tube. A further 3
mL of basic water was used to rinse the centrifuge tubes and this wash solution was
added to the 5 mL tube for a final volume of 5 mL. The particle solution was then put
in the freezer for one hour followed by lyophilization for 24 hours. A schematic of this
process can be found in Figure 6.
The mean size (diameter), polydispersity index (PDI), and zeta potential of the
particles was determined using a Malvern Zetasizer Nano ZS capable of dynamic light
scattering (DLS) and zeta potential measurement. The shape and surface morphology
of particles was evaluated by scanning electron microscopy (SEM), using a Zeiss
SIGMA VP Field Emission-Scanning Electron Microscope (FE-SEM). For SEM
evaluation, samples were placed on aluminum stubs (TedPella, Inc., Redding, CA,
USA) and were then coated with a gold/palladium alloy thin film using an Emscope
SC400 sputter coating system at 20 mA for 30 seconds under argon gas. The electron
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Figure 6: Schematic of nanoparticle synthesis via single emulsion/solvent
evaporation method.
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beam with an accelerating voltage of 5 to 10 kV was used at a working distance of
13.3 to 15.3 mm. Images were captured at several magnifications.
The encapsulation efficiency, drug loading, and drug release of PTX and IM
loaded nanoparticle determined by dissolving the particles completely in acrylonitrile
and methanol, respectively, and analyzing these results via Ultra Performance Liquid
Chromatography (UPLC). PTX nanoparticles drug release behavior was analyzed by
placing the particles in a physiologically buffered modified release medium (pH 7.4)
containing PBS, 4 weight % Kolliphore EL, and 2.4 weight % Tween 20 to enhance
the solubility of PTX upon release. Imatinib-loaded nanoparticles release behavior was
analyzed by placing the particles in a physiologically buffered medium (pH 7.4). The
release took place at 37°C and 100 rpm.
UPLC was performed using a Hitachi analytical HPLC system with D-700 HPLC
System Manager software for data analysis. The separation was achieved using an
Ascentis® C-18 HPLC column (4.6 mm x 15 cm, 5 μm pore size). The mobile phase
for paclitaxel detection consisted of acetonitrile and water (50:50 v/v) with a 20 μL
injection volume and 1.0 ml/min mobile phase flow rate. The column eluate was
evaluated at 227 nm for the detection of paclitaxel in the samples. The mobile phase
for imatinib detection consisted of 50 volume % methanol and 50 volume % aqueous
formic acid (0.5 volume % in water) with a 20 μL injection volume and 1.2 ml/min
mobile phase flow rate. The column eluate was evaluated at 270 nm for the detection
of IM in the samples. For both the PTX and IM evaluation, calibration curves (Figure
A1 and Figure A2, respectively) were generated using UPLC as described above.
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These calibration curves are present in Appendix A. From this analysis the
encapsulation efficiency and drug loading of the nanoparticles were evaluated as:

Encapsulation Efficiency =

Actual Mass of Drug in Nanoparticles
x 100%
Theoretical Mass of Drug in Nanoparticles

Drug Loading =

Actual Mass of Drug in Nanoparticles
Mass of Nanoparticles

Furthermore, the percent of drug released was evaluated from:

Drug Release (%) =

Mt
M∞

where Mt is the mass of the drug at time point (t) and M is the mass of drug in
sample.
Thermal analysis and phase transition measurements were carried out using a TA
Q10 differential scanning calorimetry (DSC) system (TA Instruments, New Castle,
DE, USA) with TA Instruments Explorer software and DSC refrigerated cooling
accessory. 1 to 5 mg of sample was weighed into hermetic anodized aluminum DSC
pans and was sealed hermetically sealed. Dry nitrogen gas was used as the purging gas
at 50 mL/min. The heating range during DSC analysis was 0 to 300 °C at a heating
scan rate of 10.00 °C/min.
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2.4 In Vitro Biological Characterization
Lung carcinoma (A549) cancer cells (obtained from American Type Culture
Collection, Manassas, VA, USA) were evaluated for their response to the
chemotherapeutic agents paclitaxel and imatinib. The base cell culture medium for the
cell line was Dulbecco's Modified Eagle Medium (DMEM). The complete medium for
cells contained DMEM with 10 % v/v fetal bovine serum (FBS), Pen-Strep (100
I.U./ml penicillin, 100 μg/ml streptomycin), Fungizone® (0.5 µg/ml amphotericin B,
0.41 µg/ml sodium deoxycholate), and 1 mM of sodium pyruvate. The cells were
cultured at 37 °C and 5 % CO2 in a humidified incubator and were used from passages
3 through 15. A549 cells were selected for the described research since these cells
have been shown to overexpress v3 integrins (Odrljin 2001, Chetty 2010) and
therefore iRGD should home to and penetrate into cells and spheroids composed of
these cells (Sugahara 2009).
Initially, for two-dimensional (2D) studies, A549 cells were seeded at 5,000
cells/well with 100 μL/well in 96 well plates and were placed in an incubator for 24
hours. For three-dimensional (3D) multicellular spheroid (MSC) cell studies, 96 round
bottom well plates were coated with 0.5 % w/v poly(2-hydroxyethyl methacrylate)
(pHEMA) in 200 proof ethanol and allowed to try for 48 hours. A549 cells were then
seeded at 5,000 cells/well, 100 μL/well, and with 20 µg collagen/ml in the media in
the coated round bottom 96 well plates. These plates were then centrifuged at 1500 rcf
for 15 minutes and were placed in the incubator for 24 hours to facilitate spheroid
compaction and formation.
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The 2D cells and 3D spheroids were then exposed to the following conditions for
48 hours: (i) raw PTX at 0.001, 0.01, 0.05, 0.1 0.5, 5 and 10 μM in complete medium
with 0.1 volume % DMSO, (ii) 0.1% PTX-loaded nanoparticles at 0.001, 0.01, 0.05,
0.1, 0.5 and 1 μM, where the PTX amount was calculated from the actual drug loading
of the nanoparticles, (iii) raw imatinib at 0.01, 0.05, 0.1, 0.5, 1, 5, 10, 50, and 100 μM
in complete medium with 0.1 volume % DMSO, and (iv) 10% imatinib-loaded
nanoparticles at 0.01, 0.05, 0.1, 0.5, 1, 5, 10, and 50 μM imatinib, where the IM
amount was calculated from the actual drug loading of the nanoparticles. The controls
for these studies were complete media with 0.1 volume % DMSO. The media
solutions contained 0.1 % (v/v) DMSO to increase PTX and IM solubility and the
DMSO control was used as a comparison to ensure no negative effects on the cells
were due to the solvent. The solutions were all initially made with double the final
concentration and 100 L of the solutions was added to each well already containing
100 L of media.
After 48 hours, a resazurin assay was used to assess the cell viability of the cells.
Resazurin is converted to highly fluorescent resorufin by cells that are alive. 20 L of
20 mM resazurin was added to each well containing cells and the well plates were
incubated for 3 hours. After this time, the samples were evaluated using a multi-mode
plate reader (Cytation 3, BioTek Instruments, Vermont, USA) at an excitation
wavelength of 544 nm and emission wavelength of 590 nm with gains of 50, 70, and
90. The relative viability of the cells was determined by the fluorescence intensity:
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Relative viability (%) =

Fluorescence Intensity of Sample
Fluorescence Intensity of Control

𝑥 100%

As seen above, these results were reported as the ratio of the fluorescence
intensity of the resorufin generated from live cells for a given sample exposed to
treatment in comparison to the fluorescence intensity generated from live cells not
exposed to drug treatment. The inherent relative viability is thus a comparison in cell
response to the given control. The corresponding half maximal inhibitory
concentration (IC50) values for raw PTX, 0.1% PTX-loaded nanoparticles, raw
imatinib, and 10% imatinib-loaded nanoparticles in the sample were determined using
the four-parameter logistic equation and were subsequently fit to this equation using
http://www.readerfit.com. The four-parameter logistic equation used to generate and
fit the dose-response curves corresponding to the relative viability and drug
concentration is defined as:

𝑉=𝐷+

𝐴−𝐷
𝑥 𝐵
1+ ( )
𝐶

where V is the relative viability, A is minimum viability of the cells at the highest
tested drug concentration, B is the Hill’s slope of the dose-response curve, C is the
IC50 value (evaluated at the inflection point of the slope), and D is the maximum
viability of the cells not exposed to any therapeutics. The actual viability values were

37

graphed along with the theoretical fit values obtained from the four-parameter logistic
equation.
To evaluate the potential uptake of nanoparticles into lung cancer cells, A549
cells were seeded at 125,000 cells/mL (300 μL/well) in 8 well chamber slides and
were placed in an incubator for 24 hours to allow time for cell attachment. The cells
were then exposed to 1 mg/mL of fluorescently-labeled drug-loaded nanoparticles in
media for 24 hours at 37 °C. These nanoparticle systems were 0.1% PTX-loaded and
10% imatinib-loaded nanoparticles with the addition of 2 weight % fluorescein
isothiocyanate (FITC) added to the organic phase during nanoparticle synthesis to
allow for fluorescent imaging of the particles. After the cells were exposed to the
nanoparticle/media solutions (up to 24 hours), the particle solutions were removed and
the cells were washed twice with 200 mM glycine to remove any unbound particles,
followed by an additional wash with PBS. The cells were then stained with 750 nM
Lysotracker Red and fixed with hardset Vectashield containing DAPI prior to imaging
with a Nikon Eclipse E600 upright microscope.
The ability of A549 cells to form spheroids and their growth with time was
evaluated using brightfield microscopy (Nikon Diaphot TMD). The spheroids were
imaged immediately after centrifugation and then each day for up to 5 days. The size
of the spheroids was analyzed using ImageJ software (Abramoff 2004).
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2.5 iRGD Conjugation and Tumor-Penetration Efficacy of Nanoparticles
Two types of iRGD were used for the studies described in this research. The first
type of iRGD was peptide with no fluorescent tag and extra cysteine (G) residues that
was synthesized, purified (99 % purity), and characterized by Rakesh Tiwari, a
collaborator in the Department of Biomedical and Pharmaceutical Sciences at the
University

of

Rhode

Island

(Kingston,

RI).

The

final

compound

(NH2-CGGGCRGDKGPDCG-CONH2) was an alkoxyamine-functionalized peptide
that could be conjugated to Ac-Dex nanoparticles owing to the ability of
polysaccharides to form stable oxime conjugates with alkoxyamine-bearing molecules
(Beaudette 2009). The second type of iRGD use in the described studies was
CRGDKGPDC labeled with a TAMRA fluorophore to allow for easy detection of the
iRGD in solution. This compound was generously donated by Anastasia Kruse, a
collaborator in the Department of Chemical Engineering at the University of Kentucky
(Lexington, KY).
As depicted in Figure 7, iRGD-conjugated nanoparticles were prepared by
mixing 5 mg of the alkoxyamine-functionalized iRGD with 1 mg of Ac-Dex
nanoparticles in 1 mL PBS. First, 5 mg of iRGD and 1 mg of nanoparticles was
measured into 1 mL of PBS and was then sonicated in a water bath for 15 minutes.
The samples were then put on a shaker at 37C and 100 rpm for 2 days. After 2 days,
the samples were centrifuged at 12,000 rcf (10629 rpm) for 15 minutes and the
supernatant was removed. The particles were washed twice with 1 mL fresh PBS and
then resuspended using sonication. 100 µL/well of particle solution was added to each
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Figure 7: Schematic depicting (i) the formation of Ac-Dex into Ac-Dex
nanoparticles (NP), (ii) reducing end chain equilibrium between hemiacetal and
straight-chain forms, and (iii) reaction of the reducing end aldehyde with
alkoxyamine-conjugated iRGD.
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well of a 96 well UV transparent plate and then 300 µL of 20 mg/mL of fluorescamine
in acetone was added to each well make the total volume 400 µL. The fluorescamine
reacts with primary amines in the iRGD to allow for the quantification of the amount
of iRGD present in solution. The amount of iRGD conjugated to the nanoparticles was
then evaluated using a fluorescence spectroscopy plate reader (Biotek Cytation3) at an
excitation wavelength of 400 nm, emission wavelength of 460 nm, and gain of 100
following one hour of incubation.
To allow for the quantification of the amount of TAMRA-iRGD present on
nanoparticles or cells, a calibration curve of TAMRA-iRGD was prepared in media
without serum as seen in Figure A3. Concentrations of 0, 0.0005, 0.0025, 0.00375,
0.005, 0.0125, 0.025, 0.0375, 0.05 mg/mL were prepared and 100 L of each
concentration/solution was added to a 96 well plate. The fluorescence of the solutions
was then read using an excitation wavelength of 540 nm and emission wavelength of
585 nm (gain values of 50, 75, and 100) using the Biotek Cytation3 plate reader.
To evaluate the affinity of TAMRA-iRGD nanoparticles to A549 lung
adenocarcinoma cells, cells were seeded at 200,000 cells/mL (100 L/well) in 96
wells plates and placed in an incubator for 24 hours. The cells were then exposed to
different concentrations of TAMRA-iRGD in media including 0, 0.0005, 0.0025,
0.00375, 0.005, 0.0125, 0.025, 0.0375, 0.05 mg/mL in serum-free media. At different
time points (0, 0.5, 1, 2, 4, 7 and 24 hours), the area-average fluorescence of the
samples was evaluated at an excitation wavelength of 540 nm and emission
wavelength of 585nm with a gain of 100 using the Biotek Cytation3 plate reader. Prior
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to analysis at each time point, the iRGD solution was removed from the wells and the
cells were washed three times with PBS to remove any unbound iRGD.
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CHAPTER 3

RESULTS AND DISCUSSION

3.1 Characterization of Acetalated Dextran (Ac-Dex)
Because of the significant differences in the rates of hydrolysis between the
acyclic and cyclic acetals present on Ac-Dex, it is important to know the cyclic acetal
coverage (CAC) of Ac-Dex to ensure that the degradation will be appropriate for the
given application. The relative proportion of cyclic and acyclic acetals was determined
by comparing the relative concentrations of acetone and methanol present during
1

H-NMR analysis. This is possible since the hydrolysis of one acyclic acetal yields

one molecule each of acetone and methanol, whereas the hydrolysis of one cyclic
acetal yields only a single acetone molecule (Bachelder 2008). The CAC was then
determined via the ratio of acetone to methanol by comparing the integration of the
acetone peak (2.08 ppm) to the methanol peak (3.34 ppm) from 1H-NMR analysis. All
integrations were normalized to the number of protons on each molecule. The
calculation protocol for this method can be found in Appendix B.
Analysis of Ac-Dex formed after a 5-minute reaction period was completed via
1

H-NMR (see Figure 8). These results showed that the cyclic acetal coverage (CAC)

of the fast degrading Ac-Dex was approximately 70%. In addition, the conversion of
hydroxyl groups on the parent dextran to acetal group was at least 80% for all batches
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Figure 8: Representative NMR spectra of acetalated dextran use for cyclic acetal
coverage (CAC) calculations.
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of Ac-Dex, indicating good coverage of acetals on the polymer backbone. The
reported CAC value is appropriate for the desired application as Ac-Dex with this
property is known to degrade with a few days (Bachelder 2008, Bachelder 2008,
Meenach 2012), which is appropriate for the application of nanoparticles to tumors.

3.2 Characterization of Drug-Loaded Ac-Dex Nanoparticles
The size (diameter), polydispersity index (PDI), zeta potential, encapsulation
efficiency, and drug loading of the nanoparticles was evaluated to show the feasibility
and efficacy of using the emulsion/solvent evaporation method for the generation of
chemotherapeutic nanoparticles. The size of both blank (no drug) and drug-loaded
Ac-Dex nanoparticles was evaluated using dynamic light scattering (DLS) and the
results are depicted in Table 4. The particles sizes range from 232 to 282 nm, which is
suitable for nanoparticles used in the applications for the systemic delivery of
nanoparticles and cancer treatment via tumor penetration and controlled delivery.
Nanoparticle formulation and surface morphologies were visualized and analyzed
via scanning electron microscopy (SEM) as seen in Figure 9. From these images it
can be seen that the nanoparticles are smooth and spherical, which is appropriate for
the indicated application. From these images it can be estimated that the diameters of
both the blank and drug-loaded nanoparticles range from 200 to 300 nm, confirming
the results gained from the DLS analysis. Finally, no differences were seen between
systems with paclitaxel (PTX), imatinib mesylate (IM), and blank nanoparticles
regarding their morphology, indicating the loading of the drug had little effect on these
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Table 4: Physicochemical characterization results for blank and drug loaded
nanoparticles including particle diameter, polydispersity index (PDI), zeta
potential, encapsulation efficiency, and drug loading (g drug/mg nanoparticles).
Data represents average values ±standard deviation for at least n = 3.

Encapsulati
Drug

Zeta
Particle

Diameter

on
PDI

System

Potential

(nm)

Loading (g
Efficiency

(mV)

drug/mg NP)
(%)

0.1% PTX

232 ±13

0.21 ±0.08

-0.40±0.02

50 ±17

0.5 ±0.17

10% Imatinib

282 ±2

0.20 ±0.02

-0.30 ±0.03

14 ±3

14 ±3

255 ±25

0.19 ±0.02

-2.43 ±0.13

----

----

Blank
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Figure 9: Scanning electron micrographs of (a) 0.1% PTX, (b) 10% imatinib, and
(c) blank acetalated dextran nanoparticles.
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characteristics in comparison to blank particles without drug.
The polydispersity index (PDI) values from Table 4 were approximately 0.20,
indicating that the nanoparticles, regardless of the presence or type of drug in the
nanoparticle systems. In addition, the zeta potential values of the nanoparticles ranged
from -2.43 to -0.30 mV, indicating that the particle systems are all nearly neutral
(Honary 2013, Honary 2013), with drug loading have no effect on this parameter.
The encapsulation efficiency of the nanoparticles was 50 % for 0.1% PTX
nanoparticles and 14 % for 10% imatinib nanoparticles. This ultimately resulted in an
actual drug loading of 0.52 g of PTX per mg of nanoparticles and 14 g of imatinib
per mg of nanoparticles. Overall, these results indicate that both PTX and imatinib can
be successfully loaded into Ac-Dex based nanoparticle systems using the
emulsion/solvent evaporation particle formation method. In addition, it seems that
there is some effect on drug loading due to either the type of drug loaded or the
amount of drug loaded into the nanoparticle systems. This could be due to the
hydrophobicity or lipophilicity of the drugs present in the nanoparticle systems.
Figure 10 shows the results from differential scanning calorimetry (DSC) for the
nanoparticle systems and raw components that made up the nanoparticles. While, the
nanoparticles were evaluated a large temperature range, these results ultimately show
that the nanoparticles are stable within a normal temperature range that nanoparticles
would be exposed to during synthesis, storage, and administration (4 to 100°C).
The release of paclitaxel and imatinib from acetalated dextran nanoparticles was
evaluated over 48 hours as seen in Figure 11 (for paclitaxel nanoparticles) and Figure
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Figure 10: Differential scanning calorimetry (DSC) thermogram of raw
acetalated dextran (Ac-Dex), blank nanoparticles without drug (Blank NPs), raw
paclitaxel (PTX), 0.1% PTX-loaded nanoparticles (0.1% PTX NPs), raw imatinib,
and 10% imatinib-loaded nanoparticles (Imatinib NPS).
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Figure 11: Amount of paclitaxel released versus time for 0.1% PTX
nanoparticles.
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Figure 12: Amount of imatinib released versus time for 10% IM nanoparticles.
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12 (for imatinib nanoparticles). The release data shows that the drug-loaded
nanoparticles (both PTX and imatinib) exhibited a burst release for the first two hours
with 40 % released from PTX-loaded nanoparticles and 60 % released from IM-loaded
nanoparticles during this time. Both systems then demonstrated controlled release after
the first two hours and the final release for both systems was completed within 48
hours.
Overall, these results demonstrate the feasibility in synthesizing PTX and
IM-loaded nanoparticles with Ac-Dex as the polymer. The systems ultimately exhibit
the desired morphological, size, charge, and shape necessary for systemic delivery to
tumors and are stable at the desired working temperatures. Furthermore, the
nanoparticles exhibit the ability to control the release of either PTX or IM for an
extended amount of time, which can enhance the efficacy of using these systems in the
treatment of lung cancer.

3.3 In Vitro Biological Characterization
The effect of raw paclitaxel, paclitaxel-loaded nanoparticles, and blank
nanoparticles on the viability of A549 lung adenocarcinoma cells was evaluated 48
hours after drug and/or nanoparticle exposure. The effect of raw PTX, PTX-loaded
nanoparticles and raw Imatinib on A549 cells can be seen in Figure 13 and 14. For
both the pure drug and PTX nanoparticles, the cell viability decreased with increasing
drug concentration as expected. Furthermore, the relative viability of A549 cells
exposed to PTX-loaded nanoparticles was lower than that for pure PTX. This
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Figure 13: Dose-response curve for A549 cells exposed to PTX and 0.1%
PTX-loaded nanoparticles.
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Figure 14: Dose-response curve for A549 cells exposed to Imatinib.
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indicated that it takes a lower concentration of drug in the nanoparticles to kill the
same number of cells as compared to the pure PTX. This is also indicated by the IC50
values, were the IC50 value for raw PTX was 0.2299 µM and for PTX NPs was
0.0695 µM. This ultimately indicates that the PTX-loaded nanoparticles are more
effective in killing lung cancer cells than pure PTX, even without iRGD conjugation.
And the IC50 of raw Imatinib was 4.0993 µM.
The effect of blank nanoparticles on A549 cells was also evaluated. The amount
of nanoparticles loaded into media for exposure to the cells was determined by using
the largest mass of nanoparticles needed for the highest concentration of PTX. The
relative viability of cells exposed to blank nanoparticles was 96 %, indicating that the
nanoparticle exert minimal to no cytotoxic effects on A549 cells. This, in turn,
demonstrates that they should be safe for administration of anticancer therapeutics.
The potential for Ac-Dex nanoparticles to be uptaken into A549 cells was
evaluated. For these initial studies, FITC-loaded nanoparticles with no drug were
evaluated by exposing the cells to nanoparticles for 5 hours. Figure 14 shows that
after 5 hours the A549 cells exhibited very minimal uptake of FITC-loaded
nanoparticles. This could potentially be attributed to the short exposure time or the
lack of peptide targeting for these nanoparticles since no iRGD was conjugated onto
the nanoparticle surfaces.
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Figure 15: Representative fluorescent image from uptake studies where A549
lung adenocarcinoma cells were exposed to FITC-loaded nanoparticles for 5
hours. The blue fluorescence indicates the cell nuclei, red indicates cellular
lysosomes, and green indicates the uptaken nanoparticles.
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Figure 16: Bright field images of three-dimensional multicellular spheroids comprised
of A549 lung adenocarcinoma cells via centrifugation. The scale bar for 0 hour is 10
m whereas the scale bar for Days 1 through 5 is 100 m.
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3.4 Three-Dimensional Multicellular Spheroid Evaluation
Three-dimensional (3D) multicellular spheroids (MCS) comprised of A549 lung
cancer cells were successfully formed using a modified centrifugation technique. In
this technique, cells in a small amount of collagen were seeded into non-adherent
round bottom 96 well plates followed by mild centrifugation. As shown in Figure 15,
immediately after centrifugation (0 hour), the cells formed a two-dimensional (2D)
confluent monolayer on the bottom of the round bottom well plates. Within 24 hours
(Day 1 image) 3D MCS have formed and continue to grow with time. These spheroids
show spherical morphology with a high density of cells within their structure.
The size of the spheroids was analyzed by using the brightfield images and
ImageJ software. As seen in Figure 16, the size of the spheroids increased with
culture time and the spheroids reached a diameter of approximately 560 m after 5
days. Overall, these results indicate the successful formation of A549 multicellular
spheroids where these systems will be used in future studies relating the
tumor-penetrating nanoparticles.

3.5 iRGD-Nanoparticle Conjugation and Affinity to A549 Cells
The amount of iRGD capable of conjugating to acetalated dextran nanoparticles
was determined using the fluorescamine assay. These results indicated that
approximately 5.618 x 104 molecules of iRGD were conjugated to each nanoparticle
and the iRGD coverage is 0.287 iRGD/nm2. Overall, these results show that acetalated
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dextran nanoparticles can be produced that will be capable of tumor homing and
penetration through the iRGD tumor penetrating mechanism.
The affinity of iRGD to A549 cells was evaluated by exposing these cells to
differing concentrations of TAMRA-conjugated iRGD for different times (up to 24
hours). These results are indicated in Figure 17, which showed that iRGD interacts
with and likely penetrates A549 lung adenocarcinoma cells. In this figure,
fluorescence intensity of the TAMRA-iRGD attached to the cells is compared to the
iRGD concentration and exposure time. After 3 hours, the fluorescence intensity of the
samples was the highest regardless of iRGD solution concentration. This indicates that
this is the optimal time period for A549 cells to interact with and uptake iRGD, which
will be useful in designing future in vitro experiments with respect to exposure time.
Overall, the fluorescence intensity of the samples increased with increasing
TAMRA-iRGD concentration. This is expected because there is a linear relationship
between the concentrations of iRGD in serum-free media with respect to fluorescence
intensity as shown by the calibration curve in Figure A3 (see Appendix A). Overall,
these studies show the feasibility in using iRGD-conjugated nanoparticles to target
A549 lung adenocarcinoma cells for the enhanced treatment of lung cancer.
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Figure 17: Diameter of three-dimensional multicellular spheroids with respect to
time. The diameter of the spheroids was evaluated using brightfield images and
ImageJ software.
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Figure 18: Results indicating the iRGD affinity to A549 lung adenocarcinoma
cells. A549 cells were exposed to different concentrations of TAMRA-iRGD for
up to 24 hours. The fluorescence intensity of the TAMRA-iRGD was then
evaluated.
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CHAPTER 4

CONCLUSIONS AND FUTURE WORK

4.1 Conclusions
Two kinds of drug-loaded nanoparticles were successfully synthesized using the
polymer acetalated dextran in this study. These systems were comprised of 0.1%
paclitaxel (PTX) and 10% imatinib-loaded nanoparticles. Overall, their physical and
chemical characteristics have been evaluated. The developed systems exhibited
favorable size (diameter), polydispersity in relation to size, and zeta potential to allow
for their use in the systemic delivery of anticancer therapeutics. Both the encapsulation
efficiency and drug loading were also favorable for the application of these
nanoparticles for potential the treatment of lung cancer.
In vitro cell studies showed that drug-loaded nanoparticles increases the efficacy
of chemotherapeutic drugs (in particular paclitaxel) for A549 lung carcinoma cells. It
is possible that chemotherapeutic drug-loaded Ac-Dex nanoparticles could be applied
in vivo to treat non-small cell lung cancer while reducing the toxic side effects of the
free drug normally delivered systemically.
For this application, drug-loaded Ac-Dex nanoparticles could potentially be
actively targeted to non-small cell lung cancer tumors and vasculature and then
penetrate into the tumors cells with the help of tumor-penetrating peptide, iRGD. This
intracellular environment would then trigger the intracellular burst release of the drug
payload due to the acid-sensitivity of the Ac-Dex polymer with minimal drug released
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in extracellular pH-neutral environments. The results of the described study indicate
that iRGD can be successfully conjugated to Ac-Dex nanoparticles and that iRGD also
shows affinity for A549 cells that are known to overexpress integrins that allow active
targeting of the nanoparticle systems. Overall, these drug-loaded nanoparticles may
have the ability to treat non-small lung cancer in addition to numerous other types of
cancer.

4.2 Future Work
The work described in this thesis is hopefully just the beginning regarding the
investigation of tandem delivery of agents using nanoparticles system for the
treatment of non-small cell lung cancer. Future work to build upon this project may
include, but is not limited to:


Optimization of nanoparticles size and encapsulation efficiency to achieve a
better effect during in vitro studies.



Investigation of the methods of loading two drugs into one nanoparticle
system to reduce side effects and allow for dual delivery.



Optimizing and evaluating the conjugation of iRGD onto blank and
drug-loaded nanoparticle systems.



Investigation into the ability of iRGD-conjugated nanoparticles to increase
the efficacy of non-iRGD nanoparticles against A549 cells on both 2D
monolayer and 3D spheroid cultures.
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Evaluating the ability of iRGD-conjugated nanoparticles to penetrate 3D
multicellular spheroids.



Evaluating the systemic efficacy of iRGD-conjugated Ac-Dex nanoparticles
in vivo in both non-small cell lung cancer cells and tissues.



Incorporation of iRGD-conjugated, drug-loaded nanoparticles with radiation
treatment to increase their therapeutic effect.
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APPENDIX A

CALIBRATION CURVES

As described in Chapter 2 (Materials and Methods), calibration curves for
paclitaxel (PTX) and imatinib mesylate (IM) were generating using ultra performance
liquid chromatography (UPLC). As seen in Figure A1, a plot of the peak area due to
the detection of PTX compared to its concentration was generated. This figure shows a
lower detection limit of 10 g/ml and upper detection limit of 80 g/ml in the mobile
phase for PTX. The R-squared value of 0.9999 shows very good fit for the described
data. A plot of peak area due to the detection of IM compared to its concentration can
be found in Figure A2. This figure shows a lower detection limit of 10 g/ml and
upper detection limit of 100 g/ml for imatinib mesylate in mobile phase with a
favorable R-squared value of 0.9944.
TAMRA-iRGD calibration curves were generated using fluorescence detection of
a plate reader as described in Chapter 2 (Materials and Methods) as seen in Figure
A3. For this detection, the lower limit was 0.0005 g/ml and the upper limit was 0.05
g/ml with a favorable R-squared value of 0.9. Finally an iRGD-fluorescamine
calibration curve was generated using fluorescence microscopy. As seen in Figure A4,
the lower limit was 0.1 mg/ml iRGD and the upper limit was 0.5 mg/ml with a
favorable R-squared value of 0.9716.
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Figure 19: Calibration curve for paclitaxel (PTX) generated using ultra
performance liquid chromatography (UPLC).
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Figure 20: Calibration curve for imatinib mesylate (IM) generated using ultra
performance liquid chromatography (UPLC).
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Figure 21: Calibration curve for TAMRA-iRGD as generated using fluorescence
spectroscopy (plate reader).
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APPENDIX B

1

H-NMR CALCULATIONS FOR AC-DEX

The cyclic acetal coverage (CAC) of Ac-Dex was determined using 1H-NMR as
described in Section 2.2 (Synthesis and Characterization of Acetalated Dextran
(Ac-Dex)). Using the software available on the equipment, the areas of characteristic
peaks of several compounds were calculated. These included the peak areas for the
hydrogen rings present in dextran (3.4 to 4.0 ppm, three peaks total), methanol (3.36
ppm), and acetone (2.08 ppm). First, a normalization factor was calculated for the
dextran peaks:

𝑁𝑜𝑟𝑚𝑎𝑙𝑖𝑧𝑎𝑡𝑖𝑜𝑛 𝐹𝑎𝑐𝑡𝑜𝑟 (𝑁𝐹) =

𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑜𝑓 𝐷𝑒𝑥𝑡𝑟𝑎𝑛 𝑃𝑒𝑎𝑘𝑠
2

where 2 is the number of protons available on each molecule. Next the amount of
methanol (MeOH) and acetone (Ace) present in the samples was calculated using the
following equations:

𝑀𝑒𝑂𝐻 =

𝐴𝑐𝑒 =

𝑀𝑒𝑡ℎ𝑎𝑛𝑜𝑙 𝑃𝑒𝑎𝑘 𝐴𝑟𝑒𝑎
3 ∗ 𝑁𝐹

𝐴𝑐𝑒𝑡𝑜𝑛𝑒 𝑃𝑒𝑎𝑘 𝐴𝑟𝑒𝑎
6 ∗ 𝑁𝐹
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where NF is the normalization factor. NF was multiplied by 3 for the methanol
samples and by 6 for the acetone samples owing to the number of hydrogen molecules
present in these compounds. Finally, the cyclic acetal coverage (CAC) was calculated
to be:

𝐶𝐴𝐶 = (𝐴𝑐𝑒 − 𝑀𝑒𝑂𝐻) 𝑥 100%

The extent of -OH hydrolysis was also calculated via 1H-NMR analysis:
𝐶𝑦𝑐𝑙𝑖𝑐 𝑎𝑐𝑒𝑡𝑎𝑙 𝑝𝑒𝑟 𝑔𝑙𝑢𝑐𝑜𝑠𝑒 = 𝐴𝑐𝑒 − 𝑀𝑒𝑂𝐻
𝐴𝑐𝑦𝑐𝑙𝑖𝑐 𝑎𝑐𝑒𝑡𝑎𝑙 𝑝𝑒𝑟 𝑔𝑙𝑢𝑐𝑜𝑠𝑒 = 𝑀𝑒𝑂𝐻
Two of the three and one of three hydroxyls on each glucose repeat unit can be
used to form a single cyclic acetal and acyclic acetal, respectively. The number of -OH
groups converted per glucose (-OH Conv) was calculated as:

−𝑂𝐻 𝐶𝑜𝑛𝑣 = 𝑀𝑒𝑂𝐻 + 2(𝐴𝑐𝑒 − 𝑀𝑒𝑂𝐻)

The percent acetalation ratio was then calculated as:

% 𝐴𝑐𝑒𝑡𝑎𝑙𝑎𝑡𝑖𝑜𝑛 =

−𝑂𝐻 𝐶𝑜𝑛𝑣
𝑥 100%
3

70

APPENDIX C

CALCULATIONS FOR DETERMINING IRGD COVERAGE

The number of iRGD molecules present on the surface of the Ac-Dex
nanoparticles was determined using the fluorescamine assay. Fluorescamine reacts
with primary amines on iRGD to allow for quantification of the amount of iRGD
present in solution. As seen in Figure 22, there is a linear relationship between the
fluorescence intensity of fluorescamine and the concentration of iRGD in PBS.
Therefore, the amount of iRGD present on nanoparticles and the iRGD coverage per
nanoparticle can be calculated from the following calculations. From the
fluorescamine assay, the mass of iRGD present in the sample (miRGD) was 0.623 mg.
From this value, the molecules of iRGD per sample was calculated as:

𝑀𝑜𝑙𝑒𝑐𝑢𝑙𝑒𝑠 𝑜𝑓 𝑖𝑅𝐺𝐷 =

𝑚𝑖𝑅𝐺𝐷 ∙ 𝑁𝐴
𝑀𝑊

where MW is the molecular weight of iRGD (1569.71 g/moles) and NA is
Avogadro’s number (6.02214 x 1023 molecules/mole). The molecules of iRGD in 1 ml
of solution was determined to be 3.969 x 1016 molecules. The number of nanoparticles
present in each sample was determined from the nanoparticle volume, density, and
mass per sample. The mass of an individual nanoparticle is calculated as:
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𝑀𝑎𝑠𝑠 𝑜𝑓 𝑠𝑖𝑛𝑔𝑙𝑒 𝑁𝑃 (𝑚𝑛 ) = 𝑉𝜌
where V is the volume of a 255 nm nanoparticle (1.413 x 107 nm3) and ρ is the
density of the nanoparticle (1 g/cm3), which is the density of most polymers. This
gives a mass of a single nanoparticle to be 1.413 x 10-11 mg. The number of
nanoparticles in a sample was then calculated from the total mass of nanoparticle (mT
= 5 mg) and mass of a single nanoparticle:

# 𝑜𝑓 𝑁𝑎𝑛𝑜𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠 =

𝑚𝑇
𝑚𝑛

where the total number of nanoparticles per sample was 7.065 x 1011. The number
of iRGD present on each nanoparticle was then calculated from the number of
nanoparticle (mn) and number of iRGD molecules:

𝑖𝑅𝐺𝐷 𝑚𝑜𝑙𝑒𝑐𝑢𝑙𝑒𝑠 𝑝𝑒𝑟 𝑛𝑎𝑛𝑜𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒 =

𝑀𝑜𝑙𝑒𝑐𝑢𝑙𝑒𝑠 𝑜𝑓 𝑖𝑅𝐺𝐷
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑁𝑎𝑛𝑜𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠

The number of iRGD molecules per nanoparticles was calculated to be 5.618 x
104. The iRGD coverage was then calculated form the number of iRGD molecules per
nanoparticle and surface area of a single nanoparticle (A = 1.96 x 105 nm2):

𝑖𝑅𝐺𝐷 𝐶𝑜𝑣𝑒𝑟𝑎𝑔𝑒 =

𝑖𝑅𝐺𝐷 𝑚𝑜𝑙𝑒𝑐𝑢𝑙𝑒𝑠 𝑝𝑒𝑟 𝑛𝑎𝑛𝑜𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒
𝐴
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It was determined that there are 0.287 molecules of iRGD per nm2 of particle
area.
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Figure 22: iRGD calibration curve as generated using fluorescence spectroscopy
(plate reader).
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